Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Associate Professor of Cell Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007

Courses Taught

  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • PHARM 495: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 393: Research Independent Study
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 710B: Cell & Molecular Biology Module II

In the News

Representative Publications

  • Killarney, Shane T., Stephen W. G. Tait, Douglas R. Green, and Kris C. Wood. “Sublethal engagement of apoptotic pathways in residual cancer.” Trends Cell Biol 34, no. 3 (March 2024): 225–38. https://doi.org/10.1016/j.tcb.2023.07.005.
  • Maltas, Jeff, Shane T. Killarney, Katherine R. Singleton, Maximilian A. R. Strobl, Rachel Washart, Kris C. Wood, and Kevin B. Wood. “Drug dependence in cancer is exploitable by optimally constructed treatment holidays.” Nat Ecol Evol 8, no. 1 (January 2024): 147–62. https://doi.org/10.1038/s41559-023-02255-x.
  • Maltas, Jeff, Shane T. Killarney, Katherine R. Singleton, Maximilian A. R. Strobl, Rachel Washart, Kris C. Wood, and Kevin B. Wood. “Author Correction: Drug dependence in cancer is exploitable by optimally constructed treatment holidays.” Nat Ecol Evol 8, no. 1 (January 2024): 176. https://doi.org/10.1038/s41559-023-02300-9.
  • Wood, Kris, Daniel Nussbaum, Colin Martz, Andrew Waters, Alejandro Barrera, Justine Rutter, Christian Cerda-Smith, et al. “Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers.,” November 2, 2023. https://doi.org/10.21203/rs.3.rs-3511242/v1.
  • Stanland, Lyla J., Hazel X. Ang, Jacob P. Hoj, Yunqiang Chu, Patrick Tan, Kris C. Wood, and Micah A. Luftig. “Table S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer,” November 1, 2023. https://doi.org/10.1158/1541-7786.24474127.